Preliminary efficacy of the dopamine agonist, pramipexole, for fibromyalgia: The first, open label, multicenter experience

Journal of Musculoskeletal Pain

Volumn 12, Issue 1, 2004, Pages 69-74

  Holman, Andrew J ^a   Neiman, Richard A ^b   Ettlinger, Robert E ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Cedar Medical Center ^*  (United States)

^c Cedar Medical Center   (United States)

Author keywords

Autonomic nervous system; Dopamine agonist; Fibromyalgia; Pramipexole

Indexed keywords

CLONAZEPAM; DOPAMINE RECEPTOR STIMULATING AGENT; LORAZEPAM; PRAMIPEXOLE; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; DOPAMINERGIC SYSTEM; DRUG EFFICACY; FIBROMYALGIA; HEALTH STATUS; HUMAN; INSOMNIA; MULTICENTER STUDY; NAUSEA; PAIN ASSESSMENT; QUESTIONNAIRE; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

EID: 3042672881     PISSN: 10582452     EISSN: None     Source Type: Journal    
DOI: 10.1300/J094v12n01_10     Document Type: Article

References (15)

1. Yunus M, Aldag J: Restless legs syndrome and leg cramps in fibromalgia syndrome: a controlled study. BMJ 312:1339, 1996.
2. Holman AJ: Safety and efficacy of lorazepam for fibromyalgia after one year. [abstract] Arthritis Rheum 42:9(suppl) A385, 1999.
3. Ondo W: Ropinirole for restless legs syndrome. Mov Disord 14(1):138-40, 1999.
4. Lin SC, Kaplan J, Burger CD, Fredrickson PA: Effect of pramipexole in treatment of resistant restless legs syndrome. Mayo Clin Proc 73(6):497-500, 1998.
5. Holman AJ: Safety and efficacy of the dopamine agonist, pramipexole, on pain score for refractory fibromyalgia. [abstract] Arthritis Rheum 43(9):A1599, 2000.
6. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL et al.: The american college of rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum 33(2):160-72, 1990.
7. Pincus T, Swearingen C, Wolfe F: Toward a multidimensional health assessment questionnaire (MDHAQ): Assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format. Arthritis Rheum 42(10): 2220 2200-30, 1999.
8. Petzke F, Clauw DJ: Sympathetic nervous system function in fibromyalgia. Curr Rheumatol Rep 2(2): 116-23, 2000.
9. Cohen H, Neumann L, Shore M, Amir M, Cassuto Y, Buskila D: Abnormal sympathovagal balance in men with fibromyalgia. J Rheum 28(3):581-9, 2001.
10. Martinez-Lavin M, Hermosillo AG: Autonomic nervous system dysfunction may explain the multisystem features of fibromyalgia. Semin Arthritis Rheum 29(4):197-9, 2000.
11. Martinez-Lavin M, Hermosillo AG, Rosas M, Soto M: Circadian studies of autonomic nervous balance in patients with fibromyalgia: A heart variability analysis. Arthritis Rheum 41(11):1966-71, 1998.
12. Raj SR, Brouillard D, Simpson CS, Hopman WM, Abdollah H: Dysautonomia among patients with fibromyalgia: A noninvasive assessment. J Rheum 27: 2660-5, 2000.
13. Moldofsky H, Scarisbrick P, England R, Smythe H: Musculoskeletal symptoms and non-REM sleep disturbance in patients with "fibrositis syndrome" and healthy subjects. Psychosom Med 37:341-351, 1975.
14. Older SA, Battafarano DF, Danning CL, Ward JA, Grady EP, Derman S, Russell IJ: The effects of delta wave sleep interruption on pain thresholds and fibromyalgia-like symptoms in healthy subjects; correlation with insulin-like growth factor I. J Rheum 25(6):1180-6. 1998.
15. Holman AJ: Pramipexole and fibromyalgia: Promise and precaution. [letter] J Rheum 2003 in press.